Unexpected responses to EGFR inhibition in NSCLC

The presence of activating mutations of the epidermal growth factor receptor (EGFR)-gene identifies a distinct and clinically relevant molecular subset of non-small-cell lung cancer. It is now well demonstrated that EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are superior to stand...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Respir Med Case Rep
Autors principals: Stella, Giulia M., Valizia, Claudio, Zorzetto, Michele, Inghilleri, Simona, Valentini, Adele, Dore, Roberto, Colombo, Sara, Valentino, Francesco, Orlandoni, Giulio, Morbini, Patrizia
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2015
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4681892/
https://ncbi.nlm.nih.gov/pubmed/26744648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2015.06.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars